HUP9901535A3 - Aryl pyrimidine derivatives, process for producing them and pharmaceutical compositions containing them - Google Patents
Aryl pyrimidine derivatives, process for producing them and pharmaceutical compositions containing themInfo
- Publication number
- HUP9901535A3 HUP9901535A3 HU9901535A HUP9901535A HUP9901535A3 HU P9901535 A3 HUP9901535 A3 HU P9901535A3 HU 9901535 A HU9901535 A HU 9901535A HU P9901535 A HUP9901535 A HU P9901535A HU P9901535 A3 HUP9901535 A3 HU P9901535A3
- Authority
- HU
- Hungary
- Prior art keywords
- producing
- pharmaceutical compositions
- compositions containing
- pyrimidine derivatives
- aryl pyrimidine
- Prior art date
Links
- -1 Aryl pyrimidine derivatives Chemical class 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1821896P | 1996-05-23 | 1996-05-23 | |
| US4037797P | 1997-03-10 | 1997-03-10 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUP9901535A2 HUP9901535A2 (hu) | 1999-09-28 |
| HUP9901535A3 true HUP9901535A3 (en) | 2002-07-29 |
Family
ID=26690869
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU9901535A HUP9901535A3 (en) | 1996-05-23 | 1997-05-14 | Aryl pyrimidine derivatives, process for producing them and pharmaceutical compositions containing them |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US5863924A (hu) |
| EP (1) | EP0901474B1 (hu) |
| JP (1) | JP2001525794A (hu) |
| KR (1) | KR100518101B1 (hu) |
| CN (1) | CN1109675C (hu) |
| AR (1) | AR007253A1 (hu) |
| AT (1) | ATE323682T1 (hu) |
| AU (1) | AU725891B2 (hu) |
| BR (1) | BR9709599A (hu) |
| CA (1) | CA2255705A1 (hu) |
| CO (1) | CO4950514A1 (hu) |
| CZ (1) | CZ291849B6 (hu) |
| DE (1) | DE69735712T2 (hu) |
| DK (1) | DK0901474T3 (hu) |
| ES (1) | ES2262178T3 (hu) |
| HK (1) | HK1020345A1 (hu) |
| HR (1) | HRP970275B1 (hu) |
| HU (1) | HUP9901535A3 (hu) |
| ID (1) | ID16969A (hu) |
| IL (1) | IL127056A (hu) |
| MA (1) | MA26431A1 (hu) |
| MY (1) | MY119181A (hu) |
| NO (1) | NO311800B1 (hu) |
| NZ (1) | NZ332802A (hu) |
| PT (1) | PT901474E (hu) |
| RU (1) | RU2189976C2 (hu) |
| SA (2) | SA05260356B1 (hu) |
| TR (1) | TR199802391T2 (hu) |
| TW (1) | TW440563B (hu) |
| UY (1) | UY24560A1 (hu) |
| WO (1) | WO1997044326A1 (hu) |
| YU (1) | YU53298A (hu) |
Families Citing this family (87)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL134748A0 (en) * | 1997-09-02 | 2001-04-30 | Du Pont Pharm Co | Heterocyclyl-substituted ring-fused pyridines and pyrimidines as corticotropin releasing hormone (crh) antagonists, useful for treating cns and stress-related disorders |
| US6040315A (en) * | 1997-10-30 | 2000-03-21 | Day; Charles E. | Antacid co-polymer of guanidine and polyethylenimine |
| DE19844291A1 (de) * | 1998-09-18 | 2000-03-23 | Schering Ag | Benzoxazin- und Benzothiazin-Derivate und deren Verwendung in Arzneimitteln |
| GB9828511D0 (en) | 1998-12-24 | 1999-02-17 | Zeneca Ltd | Chemical compounds |
| EP1144390A2 (en) * | 1999-01-22 | 2001-10-17 | Amgen Inc., | Kinase inhibitors |
| US6495558B1 (en) | 1999-01-22 | 2002-12-17 | Amgen Inc. | Kinase inhibitors |
| DK1057831T3 (da) | 1999-05-26 | 2005-01-31 | Hoffmann La Roche | Fremgangsmåde til fremstilling af vinylpyrimidinderivater |
| CA2378710A1 (en) * | 1999-07-30 | 2001-02-08 | Pharmagene Laboratories Ltd. | Use of 2-amino-4-(4-fluoronaphth-1-yl)-6-isopropylpyrimidine in the treatment of gi disorders |
| GB9919778D0 (en) | 1999-08-21 | 1999-10-27 | Zeneca Ltd | Chemical compounds |
| HUP0202682A3 (en) | 1999-09-10 | 2003-03-28 | Merck & Co Inc | Tyrosine kinase inhibitors, pharmaceutical compositions containing them and their use |
| US7101869B2 (en) | 1999-11-30 | 2006-09-05 | Pfizer Inc. | 2,4-diaminopyrimidine compounds useful as immunosuppressants |
| KR100521735B1 (ko) * | 2000-02-25 | 2005-10-17 | 에프. 호프만-라 로슈 아게 | 아데노신 수용체 조절인자 |
| GB0004888D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| GB0004887D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| GB0004890D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| GB0004886D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| GB0007371D0 (en) | 2000-03-28 | 2000-05-17 | Astrazeneca Uk Ltd | Chemical compounds |
| GB0016877D0 (en) | 2000-07-11 | 2000-08-30 | Astrazeneca Ab | Chemical compounds |
| GB0021726D0 (en) | 2000-09-05 | 2000-10-18 | Astrazeneca Ab | Chemical compounds |
| US6444477B1 (en) | 2000-11-28 | 2002-09-03 | Pharmagene Laboratories Limited | Assay method for detecting 5-HT2B antagonists |
| GB0103926D0 (en) | 2001-02-17 | 2001-04-04 | Astrazeneca Ab | Chemical compounds |
| SK13752003A3 (en) * | 2001-05-14 | 2004-11-03 | Bristol Myers Squibb Pharma Co | Substituted pyrazinones, pyridines and pyrimidines as ligands of factor releasing corticotropine |
| GB0113041D0 (en) | 2001-05-30 | 2001-07-18 | Astrazeneca Ab | Chemical compounds |
| WO2002102313A2 (en) * | 2001-06-19 | 2002-12-27 | Bristol-Myers Squibb Company | Pyrimidine inhibitors of phosphodiesterase (pde) 7 |
| US6825198B2 (en) * | 2001-06-21 | 2004-11-30 | Pfizer Inc | 5-HT receptor ligands and uses thereof |
| ES2255621T3 (es) | 2001-06-22 | 2006-07-01 | MERCK & CO., INC. | Inhibidores de tirosina quinasa. |
| TWI329105B (en) * | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| JP2005526720A (ja) * | 2002-02-13 | 2005-09-08 | ファーマジーン ラボラトリーズ リミテッド | ５−ｈｔ２ｂ受容体アンタゴニスト |
| GB0203412D0 (en) | 2002-02-13 | 2002-04-03 | Pharmagene Lab Ltd | 5-HT 2B receptor antagonists |
| GB0205690D0 (en) | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
| GB0205688D0 (en) | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
| EP1490354A1 (en) | 2002-03-09 | 2004-12-29 | Astrazeneca AB | 4-imidazolyl substituted pyrimidine derivatives with cdk inhibitory activity |
| GB0205693D0 (en) | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
| US20040023978A1 (en) * | 2002-07-24 | 2004-02-05 | Yu Ren | Active salt forms with tyrosine kinase activity |
| US20040023981A1 (en) * | 2002-07-24 | 2004-02-05 | Yu Ren | Salt forms with tyrosine kinase activity |
| US6872724B2 (en) | 2002-07-24 | 2005-03-29 | Merck & Co., Inc. | Polymorphs with tyrosine kinase activity |
| ATE451104T1 (de) * | 2002-07-29 | 2009-12-15 | Rigel Pharmaceuticals Inc | Verfahren zur behandlung oder pruvention von autoimmunkrankheiten mit 2,4-pyrimidindiamin- verbindungen |
| UA80767C2 (en) * | 2002-12-20 | 2007-10-25 | Pfizer Prod Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
| US7109337B2 (en) * | 2002-12-20 | 2006-09-19 | Pfizer Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
| RS20060097A (en) * | 2002-12-20 | 2008-11-28 | Pfizer Products Inc., | Pyrimidine derivatives for the treatment of abnormal cell growth |
| GB0311276D0 (en) | 2003-05-16 | 2003-06-18 | Astrazeneca Ab | Chemical compounds |
| GB0311274D0 (en) | 2003-05-16 | 2003-06-18 | Astrazeneca Ab | Chemical compounds |
| WO2005012263A1 (en) * | 2003-07-24 | 2005-02-10 | Pharmagene Laboratories Limited | 5-ht2b receptor antagonists |
| CN100441228C (zh) * | 2003-07-25 | 2008-12-10 | 西巴特殊化学制品控股公司 | 取代的2,4-双(烷基氨基)嘧啶或-喹唑啉作为抗菌剂的用途 |
| PL1656372T3 (pl) * | 2003-07-30 | 2013-08-30 | Rigel Pharmaceuticals Inc | Związki 2,4-pirymidynodiaminy do stosowania w leczeniu lub zapobieganiu chorobom autoimmunologicznym |
| EP1679309A4 (en) * | 2003-10-24 | 2007-03-28 | Ono Pharmaceutical Co | ANTISTRESS MEDICAMENT AND ITS MEDICAL USE |
| JP2007519754A (ja) * | 2004-01-30 | 2007-07-19 | スミスクライン ビーチャム コーポレーション | 化合物 |
| TW200528101A (en) | 2004-02-03 | 2005-09-01 | Astrazeneca Ab | Chemical compounds |
| US20080161419A1 (en) | 2004-02-20 | 2008-07-03 | Shinobu Akuzawa | Prophylactic Antimigraine Agents |
| DE602005024382D1 (de) * | 2004-04-13 | 2010-12-09 | Astellas Pharma Inc | Polycyclische pyrimidine als kaliumionenkanal-modulatoren |
| US20060205945A1 (en) * | 2004-05-14 | 2006-09-14 | Pfizer Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
| BRPI0510963A (pt) * | 2004-05-14 | 2007-11-20 | Pfizer Prod Inc | derivados pirimidina para o tratamento do crescimento anormal de células |
| MXPA06011658A (es) * | 2004-05-14 | 2006-12-14 | Pfizer Prod Inc | Derivados de pirimidina para el tratamiento del crecimiento celular anormal. |
| BRPI0510980A (pt) * | 2004-05-14 | 2007-11-27 | Pfizer Prod Inc | derivados de pirimidina para o tratamento do crescimento anormal de células |
| RU2007110731A (ru) * | 2004-09-23 | 2008-10-27 | Редди Юс Терапевтикс | Новые соединения пиримидина, способ их получения и содержащие их композиции |
| US7557207B2 (en) | 2004-11-24 | 2009-07-07 | Rigel Pharmaceuticals, Inc. | Spiro 2,4-pyrimidinediamine compounds and their uses |
| GB0500492D0 (en) * | 2005-01-11 | 2005-02-16 | Cyclacel Ltd | Compound |
| BRPI0606318B8 (pt) | 2005-01-19 | 2021-05-25 | Rigel Pharmaceuticals Inc | composto, composição, e, uso de um composto |
| CN101151249B (zh) * | 2005-03-31 | 2011-04-06 | 辉瑞产品公司 | 环戊吡啶及四氢喹啉衍生物 |
| JP2008540436A (ja) * | 2005-05-03 | 2008-11-20 | ライジェル ファーマシューティカルズ， インコーポレイテッド | Ｊａｋキナーゼインヒビターおよびそれらの使用 |
| EP1890703B1 (en) * | 2005-06-14 | 2016-05-11 | Taigen Biotechnology | Pyrimidine compounds as chemokine receptors inhibitors |
| US8193206B2 (en) | 2005-06-14 | 2012-06-05 | Taigen Biotechnology Co., Ltd. | Pyrimidine compounds |
| US7745428B2 (en) | 2005-09-30 | 2010-06-29 | Astrazeneca Ab | Imidazo[1,2-A]pyridine having anti-cell-proliferation activity |
| US20080293942A1 (en) * | 2005-11-28 | 2008-11-27 | Cousins Russell D | Methods of Preparing 2-Imidazol-1-Yl-4-Methyl-6-Pyrrolidin-2-Yl-Pyrimidine and 4-(1-Alkylpyrrolidin-2-Yl)-2-(1H-Imidazol-1-Yl)-6-Methylpyrimidine Derivatives |
| CA2642619A1 (en) | 2006-02-20 | 2007-08-30 | Astellas Pharma Inc. | Pyrrole derivative or salt thereof |
| AR061185A1 (es) | 2006-05-26 | 2008-08-13 | Chugai Pharmaceutical Co Ltd | Compuestos heterociclicos como inhibidores de hsp90. composiciones farmaceuticas. |
| EP2094681A1 (en) * | 2006-12-22 | 2009-09-02 | Novartis AG | Indol-4-yl-pyrimidinyl-2-yl-amine derivatives and use thereof as cyclin dependant kinase inhibitors |
| RU2009136343A (ru) | 2007-03-01 | 2011-04-10 | Чугаи Сейяку Кабусики Кайся (Jp) | Макроциклическое соединение |
| CN103951658B (zh) | 2007-04-18 | 2017-10-13 | 辉瑞产品公司 | 用于治疗异常细胞生长的磺酰胺衍生物 |
| KR101294731B1 (ko) * | 2007-06-04 | 2013-08-16 | 삼성디스플레이 주식회사 | 어레이 기판, 이를 갖는 표시패널 및 이의 제조방법 |
| MX2010002004A (es) * | 2007-08-22 | 2010-03-11 | Irm Llc | Compuestos de 5-(4-(halo-alcoxi)-fenil)-pirimidin-2-amina y composiciones con inhibidores de cinasa. |
| RU2378278C2 (ru) * | 2008-01-24 | 2010-01-10 | Андрей Александрович Иващенко | ЗАМЕЩЕННЫЕ 3-СУЛЬФОНИЛ-[1,2,3]ТРИАЗОЛО[1,5-a]ПИРИМИДИНЫ-АНТАГОНИСТЫ СЕРОТОНИНОВЫХ 5-HT6 РЕЦЕПТОРОВ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЕ |
| NZ594937A (en) | 2008-02-19 | 2013-03-28 | Adolor Corp | Beloxepin, its enantiomers, and analogs thereof for the treatment of pain |
| US8372849B2 (en) | 2008-04-21 | 2013-02-12 | Taigen Biotechnology Co., Ltd. | Heterocyclic compounds |
| PL2432767T3 (pl) * | 2009-05-19 | 2013-11-29 | Dow Agrosciences Llc | Związki i sposoby zwalczania grzybów |
| EP2519519A4 (en) | 2009-12-30 | 2013-04-24 | Arqule Inc | SUBSTITUTED NAPHTHALENYL-PYRIMIDINE COMPOUNDS |
| CN102786512A (zh) * | 2012-05-31 | 2012-11-21 | 中国人民解放军军事医学科学院毒物药物研究所 | N-芳基不饱和稠环叔胺类化合物及其制备方法和抗肿瘤应用 |
| US10336768B2 (en) | 2014-06-13 | 2019-07-02 | Yuma Therapeutics, Inc. | Pyrimidine compounds and methods using the same |
| CN104725322B (zh) * | 2015-02-16 | 2017-05-24 | 同济大学 | 一种2‑胺基嘧啶类化合物及其制备方法 |
| EP3312179B1 (en) * | 2015-04-29 | 2019-07-10 | Nanjing Sanhome Pharmaceutical Co., Ltd. | Fused-ring or tricyclic aryl pyrimidine compound used as kinase inhibitor |
| RU2605265C1 (ru) * | 2015-10-06 | 2016-12-20 | федеральное государственное бюджетное образовательное учреждение высшего образования "Санкт-Петербургская государственная химико-фармацевтическая академия" Министерства здравоохранения Российской Федерации (ФГБОУ ВО СПХФА Минздрава России) | Анальгезирующее и противовоспалительное средство на основе 5-бутил-6-гидрокси-2-метилпиримидин-4(3h)-она |
| AR110038A1 (es) | 2016-05-26 | 2019-02-20 | Kalyra Pharmaceuticals Inc | Compuestos inhibidores de egfr; composición farmacéutica que lo comprende; métodos para mejorar o tratar un cáncer; método para inhibir la replicación de un crecimiento maligno o un tumor; métodos para inhibir la actividad del egfr; y usos de los compuestos |
| US10793551B2 (en) | 2017-10-19 | 2020-10-06 | Effector Therapeutics Inc. | Benzimidazole-indole inhibitors of Mnk1 and Mnk2 |
| CN108904503B (zh) * | 2018-07-02 | 2021-09-28 | 陕西科技大学 | 6-氯-5-硝基-2,4-二氨基嘧啶在治疗慢性粒细胞白血病药物中的应用 |
| AU2020289465A1 (en) * | 2019-06-06 | 2021-12-09 | Arcus Biosciences, Inc. | Processes for preparing aminopyrimidine compounds |
| AR122450A1 (es) * | 2020-05-08 | 2022-09-14 | Lilly Co Eli | Compuestos de (trifluorometil)pirimidin-2-amina |
| CN114907273A (zh) * | 2022-06-09 | 2022-08-16 | 乐威医药（江苏）股份有限公司 | 2-氨基嘧啶-6-芳基化合物的制备方法 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3535330A (en) * | 1968-04-29 | 1970-10-20 | Sandoz Ag | 2,6-diphenyl - 4 - (p-(dilower-alkyl amino lower - alkoxy)phenyl)pyridines and derivatives thereof |
| US3965101A (en) * | 1973-07-26 | 1976-06-22 | E. R. Squibb & Sons, Inc. | 1-(O-Bromo-phenoxyalkyl)-1,2-dihydro-2-iminopyrimidines |
| DE2750288A1 (de) * | 1977-11-10 | 1979-05-17 | Thomae Gmbh Dr K | Neue 9-(omega-heteroarylamino- alkylamino)-erythromycine, ihre salze, verfahren zu ihrer herstellung und diese enthaltende arzneimittel |
| US4543248A (en) * | 1979-03-19 | 1985-09-24 | The Upjohn Company | Method for immunoregulation with 6-aryl pyrimidine compounds |
| US4665077A (en) * | 1979-03-19 | 1987-05-12 | The Upjohn Company | Method for treating rejection of organ or skin grafts with 6-aryl pyrimidine compounds |
| US5002951A (en) * | 1979-03-19 | 1991-03-26 | The Upjohn Company | Method for treating bacterial and protozoal infections |
| GB2056449A (en) * | 1979-08-08 | 1981-03-18 | Searle & Co | 8-substituted-7-phenyl-1,2,4- triazolo[4,3-c] pyrimidine-5-amines and amides |
| US4619933A (en) * | 1979-09-28 | 1986-10-28 | The Upjohn Company | 6-aryl pyrimidines for treating aplastic anemia |
| FR2539741A1 (fr) * | 1983-01-21 | 1984-07-27 | Sanofi Sa | Composes a noyau heterocyclique diazote, leur procede de preparation et les medicaments, actifs sur le systeme nerveux central, qui en contiennent |
| US4512993A (en) * | 1983-07-25 | 1985-04-23 | Sterling Drug Inc. | 4(Or 5)-(pyridinyl)-2-pyrimidinamines and cardiotonic use thereof |
| US4504482A (en) * | 1983-07-28 | 1985-03-12 | Sterling Drug Inc. | [5(or 4)-(Pyridinyl)-2-pyrimidinyl]ureas and cardiotonic use thereof |
| WO1986004583A1 (en) * | 1985-02-05 | 1986-08-14 | The Upjohn Company | 4-substituted-6-aryl pyrimidine compounds |
| US4711888A (en) * | 1985-07-24 | 1987-12-08 | Pfizer Inc. | Hydroxy and alkoxy pyrimidines |
| US4929726A (en) * | 1988-02-09 | 1990-05-29 | Georgia State University Foundation, Inc. | Novel diazines and their method of preparation |
| AU3752589A (en) * | 1988-05-16 | 1989-12-12 | Georgia State University Research Foundation, Inc. | Nucleic acid interacting unfused heteropolycyclic compounds |
| HU206337B (en) * | 1988-12-29 | 1992-10-28 | Mitsui Petrochemical Ind | Process for producing pyrimidine derivatives and pharmaceutical compositions |
| IE63502B1 (en) * | 1989-04-21 | 1995-05-03 | Zeneca Ltd | Aminopyrimidine derivatives useful for treating cardiovascular disorders |
| GB9012311D0 (en) * | 1990-06-01 | 1990-07-18 | Wellcome Found | Pharmacologically active cns compounds |
| JP2648897B2 (ja) * | 1991-07-01 | 1997-09-03 | 塩野義製薬株式会社 | ピリミジン誘導体 |
| DE4237768A1 (en) * | 1991-11-12 | 1993-05-13 | Ciba Geigy Ag | New polyarylene ether derivs. with reduced viscosity - used to prepare moulded bodies, foils, fibres and membranes, as matrix resins, adhesives or coating agents or as polymer additives |
| US5698444A (en) * | 1993-12-23 | 1997-12-16 | Eli Lilly And Company | Serotonin receptor protein and related nucleic acid compounds |
| US5688807A (en) * | 1994-03-11 | 1997-11-18 | Eli Lilly And Company | Method for treating 5HT2B receptor related conditions |
| KR100275300B1 (ko) * | 1995-04-13 | 2000-12-15 | 고바야시 유키오 | 신규 4,6-디아릴피리미딘 유도체 및 그 염(novel 4,6-diarylpyrimidine derivatives and salts thereof) |
| US5795905A (en) * | 1995-06-06 | 1998-08-18 | Neurocrine Biosciences, Inc. | CRF receptor antagonists and methods relating thereto |
-
1997
- 1997-05-09 TW TW086106209A patent/TW440563B/zh not_active IP Right Cessation
- 1997-05-14 JP JP54148297A patent/JP2001525794A/ja not_active Ceased
- 1997-05-14 EP EP97923071A patent/EP0901474B1/en not_active Expired - Lifetime
- 1997-05-14 KR KR10-1998-0709451A patent/KR100518101B1/ko not_active IP Right Cessation
- 1997-05-14 RU RU98123001/04A patent/RU2189976C2/ru not_active IP Right Cessation
- 1997-05-14 DE DE69735712T patent/DE69735712T2/de not_active Expired - Fee Related
- 1997-05-14 WO PCT/EP1997/002454 patent/WO1997044326A1/en active IP Right Grant
- 1997-05-14 HU HU9901535A patent/HUP9901535A3/hu unknown
- 1997-05-14 BR BR9709599A patent/BR9709599A/pt not_active Application Discontinuation
- 1997-05-14 CA CA002255705A patent/CA2255705A1/en not_active Abandoned
- 1997-05-14 AT AT97923071T patent/ATE323682T1/de not_active IP Right Cessation
- 1997-05-14 TR TR1998/02391T patent/TR199802391T2/xx unknown
- 1997-05-14 AU AU28978/97A patent/AU725891B2/en not_active Ceased
- 1997-05-14 DK DK97923071T patent/DK0901474T3/da active
- 1997-05-14 CN CN97196018A patent/CN1109675C/zh not_active Expired - Fee Related
- 1997-05-14 CZ CZ19983803A patent/CZ291849B6/cs not_active IP Right Cessation
- 1997-05-14 IL IL12705697A patent/IL127056A/xx not_active IP Right Cessation
- 1997-05-14 PT PT97923071T patent/PT901474E/pt unknown
- 1997-05-14 ES ES97923071T patent/ES2262178T3/es not_active Expired - Lifetime
- 1997-05-14 NZ NZ332802A patent/NZ332802A/xx unknown
- 1997-05-20 US US08/858,964 patent/US5863924A/en not_active Expired - Fee Related
- 1997-05-20 HR HR970275A patent/HRP970275B1/xx not_active IP Right Cessation
- 1997-05-20 MY MYPI97002204A patent/MY119181A/en unknown
- 1997-05-21 MA MA24630A patent/MA26431A1/fr unknown
- 1997-05-22 CO CO97028097A patent/CO4950514A1/es unknown
- 1997-05-22 AR ARP970102176A patent/AR007253A1/es unknown
- 1997-05-22 UY UY24560A patent/UY24560A1/es not_active IP Right Cessation
- 1997-05-23 ID IDP971727A patent/ID16969A/id unknown
- 1997-07-01 SA SA05260356A patent/SA05260356B1/ar unknown
- 1997-07-01 SA SA97180191A patent/SA97180191B1/ar unknown
-
1998
- 1998-11-19 NO NO19985392A patent/NO311800B1/no not_active Application Discontinuation
- 1998-11-23 YU YU53298A patent/YU53298A/sr unknown
-
1999
- 1999-11-29 HK HK99105532A patent/HK1020345A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP9901535A3 (en) | Aryl pyrimidine derivatives, process for producing them and pharmaceutical compositions containing them | |
| HUP9802323A3 (en) | Pyrimidine derivatives , process for producing them and pharmaceutical compositions containing them | |
| HUP9902850A3 (en) | Quinazoline derivatives, process for producing them and pharmaceutical compositions containing them | |
| HUP0002893A3 (en) | Substituted quinazoline derivatives, process for producing them and pharmaceutical compositions containing them | |
| HUP9700344A2 (en) | Substituted quinazoline derivatives, process for producing them and pharmaceutical compositions containing them | |
| HUP9904521A3 (en) | Piperazine derivatives, process for producing them and pharmaceutical compositions containing them | |
| HUP0100723A3 (en) | Indole derivatives, process for producing them and pharmaceutical compositions containing them | |
| HUP0001802A3 (en) | Pyrazine derivatives, process for producing them and pharmaceutical compositions containing them | |
| HUP0003141A3 (en) | 4-phenylpiperidine derivatives, process for producing them and pharmaceutical compositions containing them | |
| HUP9802839A3 (en) | Quinazoline derivatives, pharmaceutical compositions containing them and process for producing them | |
| HUP9802565A3 (en) | N-benzyl-dioxothiazolidinylmethyl-benzamide derivatives, pharmaceutical compositions containing them and process for producing the same | |
| HUP9900120A3 (en) | Benzosulfone derivatives, process for producing them and pharmaceutical compositions containing them | |
| HUP9602511A3 (en) | Aryl-diazinone derivatives, pharmaceutical compositions containing them, and process for producing all these | |
| HUP9602489A2 (en) | Piperazine derivatives, process for producing them and pharmaceutical compositions containing them | |
| HUP9701265A3 (en) | Imidazoline derivatives, process for producing them and pharmaceutical compositions containing them | |
| HUP9701264A3 (en) | Aminoacid derivatives, process for producing them and pharmaceutical compositions containing them | |
| HUP9802653A3 (en) | Substituted imidazolidine derivatives, process for producing them, and pharmaceutical compositions containing them | |
| HUP0003608A2 (en) | Tetrahydroisoquinoline derivatives, process for producing them and pharmaceutical compositions containing them | |
| HUP9901739A3 (en) | Aminoisoquinolines and aminothienopyridine derivatives, process for producing thereof and pharmaceutical compositions containing them | |
| HUP0003267A3 (en) | Heteroaryl derivatives, pharmaceutical compositions containing them and process for producing them | |
| HUP9602681A1 (en) | Hydroxy-pyridinone derivatives, process for producing them and pharmaceutical compositions containing them | |
| HUP9802121A3 (en) | Imidazoline derivatives, process for producing them and pharmaceutical compositions containing them | |
| HUP0003148A2 (en) | Cyanoguanidine derivatives, process for producing them and pharmaceutical compositions containing them | |
| HUP0003150A2 (en) | Cyanoguanidine derivatives, process for producing them and pharmaceutical compositions containing them | |
| HUP0100785A3 (en) | Indole derivatives, process for producing them and pharmaceutical compositions containing them |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA9A | Lapse of provisional patent protection due to relinquishment or protection considered relinquished |